You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

À propos des lignes directrices

Biologic Therapy & Biosimilars

The guidelines and other documents available here provide recommendations related to biologic therapy for people affected by cancer in Ontario.

Biosimilars Resources for Providers

Displaying Guidelines

33 articles

Systemic Treatment Emergency Preparedness Guidance Document

Document Status: Current

Updated

Aug 2025

The Continued Use of Trastuzumab Beyond Disease Progression in Patients with Metastatic Breast Cancer

Document Status: Archived
ID: CED 13

Jun 2009

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Document Status: Current
ID: GL END 2-31

Jul 2018

The Use of Bevacizumab in Metastatic Breast Cancer

Document Status: Archived
ID: CED 12

Apr 2009

The Use of Epidermal Growth Factor Receptor Inhibitors in Advanced Colorectal Cancer

Document Status: Archived
ID: CED 8

Jul 2008

The Use of Imatinib Mesylate (GleevecTM) in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Document Status: Archived
ID: CED 10

Sep 2008

The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer

Document Status: In-Review
ID: 7-22

Aug 2015

Treatment of Chronic Myeloid Leukemia with Imatinib

Document Status: Archived
ID: 6-15

Dec 2013

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib (Iressa®), Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icotinib in the Treatment of Non–SmallCell Lung Cancer: A Clinical Practice Guideline

Document Status: In-Review
ID: 7-9
Version: 2

Apr 2014